Safety profile and discontinuation of mirabegron 50 mg, mirabegron 100 mg and tolterodine 4 mg for patients with overactive bladder/storage LUTS: a systematic review and meta-analysis

Salvi M1, Sebastianelli A1, Russo G I2, Spatafora P1, Carini M1, Serni S1, Cimino S3, Moncada I4, Gravas S5, Giuliano F6, Morgia G3, Gacci M1

Research Type

Clinical

Abstract Category

Overactive Bladder

Abstract 4
Best Clinical
Scientific Podium Session 1
Wednesday 13th September 2017
09:45 - 10:00
Cavaniglia A
Detrusor Overactivity Urgency/Frequency Nocturia Overactive Bladder
1. Department of Urology, University of Florence, Careggi Hospital, Florence, Italy., 2. Department of Urology, Policlinico Hospital, University of Catania, Catania, Italy., 3. Department of Urology, University of Catania, Catania, Italy, 4. Department of Urology, Hospital La Zarzuela, Madrid, Spain, 5. Department of Urology, University Hospital of Larissa, Larissa, Greece, 6. AP-HP, Neuro-Uro-Andrology, Versailles Saint Quentin en Yvelines University, Versailles, France
Presenter
A

Arcangelo Sebastianelli
Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
Links

Abstract

22/11/2024 20:49:50